U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H25NO2
Molecular Weight 263.3758
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRAMADOL

SMILES

CN(C)C[C@@]1([H])CCCC[C@@]1(c2cccc(c2)OC)O

InChI

InChIKey=TVYLLZQTGLZFBW-ZBFHGGJFSA-N
InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1

HIDE SMILES / InChI

Molecular Formula C16H25NO2
Molecular Weight 263.3758
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: https://www.drugs.com/tramadol.html | https://www.drugbank.ca/drugs/DB00193 | http://reference.medscape.com/drug/ultram-er-tramadol-343324 |

Tramadol (sold under the brand name Ultram) is a narcotic analgesic proposed for moderate to severe pain. Tramadol and its O-desmethyl metabolite (M1) are selective, weak OP3-receptor agonists. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. The analgesic properties of Tramadol can be attributed to norepinephrine and serotonin reuptake blockade in the CNS, which inhibits pain transmission in the spinal cord. The (+) enantiomer has the higher affinity for the OP3 receptor and preferentially inhibits serotonin uptake and enhances serotonin release. The (-) enantiomer preferentially inhibits norepinephrine reuptake by stimulating alpha(2)-adrenergic receptors. Tramadol is used primarily to treat mild-severe pain, both acute and chronic. Its analgesic effects take about one hour to come into effect and 2 h to 4 h to peak after oral administration with an immediate-release formulation. On a dose-by-dose basis, tramadol has about one-tenth the potency of morphine and is approximately equally potent when compared to pethidine and codeine. The most common adverse effects of tramadol include nausea, dizziness, dry mouth, indigestion, abdominal pain, vertigo, vomiting, constipation, drowsiness, and headache. Compared to other opioids, respiratory depression and constipation are considered less of a problem with tramadol.

Originator

Sources: Oyo Yakuri (1973), 7, (7), 1087-95.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ULTRAM

Approved Use

Tramadol hydrochloride extended-release tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

Launch Date

794188800000
Primary
ULTRAM

Approved Use

Tramadol hydrochloride extended-release tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

Launch Date

794188800000
Primary
ULTRAM

Approved Use

Tramadol hydrochloride extended-release tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

Launch Date

794188800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
332 ng/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TRAMADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
70 ng/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
O-DESMETHYLTRAMADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5678 ng × h/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TRAMADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
1319 ng × h/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
O-DESMETHYLTRAMADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TRAMADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
Health Status: healthy
Age Group: 28
Sex: M+F
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (75%)
Vomiting (50%)
Headache (25%)
Dizziness postural (25%)
Vertigo (25%)
Dizziness (12.5%)
Pruritus (37.5%)
Decreased appetite (25%)
Hot flush (12.5%)
Sources:
1500 mg single, oral
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
Health Status: unknown
Age Group: 41
Sex: M+F
Sources:
Other AEs: Seizure, Nausea and vomiting...
Other AEs:
Seizure (14.5%)
Nausea and vomiting (53.5%)
Tachycardia (4.8%)
Hypertension (mild, 38.4%)
Arrhythmia (5.3%)
Sources:
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Other AEs: Anorexia, Dry mouth...
Other AEs:
Anorexia (5.7%)
Dry mouth (13.1%)
Insomnia (5%)
Sweating (6.7%)
Asthenia (8.6%)
Pruritus (7.3%)
Arthralgia (5%)
Headache (19%)
Nausea (25.1%)
Somnolence (16.1%)
Dizziness (13.6%)
Constipation (21.3%)
Vomiting (9.3%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness 12.5%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
Health Status: healthy
Age Group: 28
Sex: M+F
Sources:
Hot flush 12.5%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
Health Status: healthy
Age Group: 28
Sex: M+F
Sources:
Decreased appetite 25%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
Health Status: healthy
Age Group: 28
Sex: M+F
Sources:
Dizziness postural 25%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
Health Status: healthy
Age Group: 28
Sex: M+F
Sources:
Headache 25%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
Health Status: healthy
Age Group: 28
Sex: M+F
Sources:
Vertigo 25%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
Health Status: healthy
Age Group: 28
Sex: M+F
Sources:
Pruritus 37.5%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
Health Status: healthy
Age Group: 28
Sex: M+F
Sources:
Vomiting 50%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
Health Status: healthy
Age Group: 28
Sex: M+F
Sources:
Nausea 75%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
Health Status: healthy
Age Group: 28
Sex: M+F
Sources:
Seizure 14.5%
1500 mg single, oral
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
Health Status: unknown
Age Group: 41
Sex: M+F
Sources:
Tachycardia 4.8%
1500 mg single, oral
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
Health Status: unknown
Age Group: 41
Sex: M+F
Sources:
Arrhythmia 5.3%
1500 mg single, oral
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
Health Status: unknown
Age Group: 41
Sex: M+F
Sources:
Nausea and vomiting 53.5%
1500 mg single, oral
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
Health Status: unknown
Age Group: 41
Sex: M+F
Sources:
Hypertension mild, 38.4%
1500 mg single, oral
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
Health Status: unknown
Age Group: 41
Sex: M+F
Sources:
Dry mouth 13.1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Dizziness 13.6%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Somnolence 16.1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Headache 19%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Constipation 21.3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Nausea 25.1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Arthralgia 5%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Insomnia 5%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Anorexia 5.7%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Sweating 6.7%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Pruritus 7.3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Asthenia 8.6%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Vomiting 9.3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
unlikely
yes
yes
likely (co-administration study)
Comment: Coadministration of quinidine, a selective inhibitor of CYP2D6, with tramadol ER resulted in a 50­ 60% increase in tramadol exposure; pharmacogenomic studies were also conducted: rapid conversion to active metabolite results in higher than expected serum M1 levels. Individuals who are ultra-rapid metabolizers should not use drug.
Page: 5
yes
likely (co-administration study)
Comment: The concomitant use of ULTRAM with cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such as rifampin, carbamazepine, and phenytoin, may result in an increase in tramadol plasma concentrations; Concomitant administration of tramadol immediate-release tablets with cimetidine, a weak CPY3A4 inhibitor, does not result in clinically significant changes in tramadol pharmacokinetics;
Page: 5
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
WHO Expert Committee on Drug Dependence. Thirty-second report.
2001
Control of non-malignant chronic pain conditions in Japan and the possible future role of tramadol.
2001
Postanaesthetic shivering: epidemiology, pathophysiology, and approaches to prevention and management.
2001
Single-dose dipyrone for acute postoperative pain.
2001
Nalbuphine by PCA-pump for analgesia following hysterectomy: bolus application versus continuous infusion with bolus application.
2001
[Control of postoperative pain in heart surgery. Comparison of analgesics].
2001 Apr
A study of pain after laparoscopic gastric banding.
2001 Apr
Tramadol for postoperative shivering: a double-blind comparison with pethidine.
2001 Apr
[Sensory neuropathy in HIV infection: pathogenesis and therapy].
2001 Apr 14
[Clinical remission of an HLA B27-positive sacroiliitis on vegan diet].
2001 Aug
Pharmacology of oral combination analgesics: rational therapy for pain.
2001 Aug
Nefopam reduces thermal hypersensitivity in acute and postoperative pain models in the rat.
2001 Dec
Analgesic efficacy of tramadol if coadministered with ondansetron.
2001 Dec
Plasma glucose-lowering effect of tramadol in streptozotocin-induced diabetic rats.
2001 Dec
Direct chiral assay of tramadol and detection of the phase II metabolite O-demethyl tramadol glucuronide in human urine using capillary electrophoresis with laser-induced native fluorescence detection.
2001 Dec 5
[Adiuvants in the axillary brachial plexus blockade. Comparison between clonidine, sufentanil and tramadol].
2001 Jan-Feb
Metabolism of the analgesic drug, tramadol hydrochloride, in rat and dog.
2001 Jul
Comparison of caudal morphine and tramadol for postoperative pain control in children undergoing inguinal herniorrhaphy.
2001 Jul
[Analysis of prehospital analgesia administered to victims with traumatic injuries].
2001 Jul-Aug
[Chronic pain in geriatrics].
2001 Jun
Direct tramadol application on sciatic nerve inhibits spinal somatosensory evoked potentials in rats.
2001 Jun
Tramadol, an alternative to morphine for treating posttraumatic pain in the prehospital situation.
2001 Jun
Treatment of refractory major depression with tramadol monotherapy.
2001 Mar
Impact of experimentally-induced expectancy on the analgesic efficacy of tramadol in chronic pain patients: a 2 x 2 factorial, randomized, placebo-controlled, double-blind trial.
2001 Mar
Efficacy and safety of dipyrone versus tramadol in the management of pain after hysterectomy: a randomized, double-blind, multicenter study.
2001 Mar-Apr
A comparison of single dose caudal tramadol, tramadol plus bupivacaine and bupivacaine administration for postoperative analgesia in children.
2001 May
[Pain in elderly patients and aspects of its therapy].
2001 May 24
A comparison of tramadol, amitriptyline, and meperidine for postepidural anesthetic shivering in parturients.
2001 Nov
Acetaminophen, aspirin, or Ibuprofen in combination analgesic products.
2001 Nov-Dec
Urinary disorders on tramadol.
2001 Oct
Distribution of enantiomers of trans-tramadol and trans-O-demethyltramadol in central nervous system of rats.
2001 Oct
Ketorolac vs tramadol in the treatment of postoperative pain during maxillofacial surgery.
2001 Sep
Multidimensional on-line solid-phase extraction (SPE) using restricted access materials (RAM) in combination with molecular imprinted polymers (MIP).
2001 Sep
Intravenous regional anaesthesia using lignocaine and tramadol.
2001 Sep
Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial.
2001 Sep
Managing postoperative pain.
2001 Sep
Effects of chronic tramadol on pre- and post-synaptic measures of monoamine function.
2001 Sep
Randomized clinical trial of Ligasure versus open haemorrhoidectomy.
2002 Feb
Combination analgesic efficacy: individual patient data meta-analysis of single-dose oral tramadol plus acetaminophen in acute postoperative pain.
2002 Feb
The addition of tramadol to lidocaine does not reduce tourniquet and postoperative pain during iv regional anesthesia.
2002 Feb
Pharmacological treatment of postoperative shivering: a quantitative systematic review of randomized controlled trials.
2002 Feb
In vivo microdialysis and conditioned place preference studies in rats are consistent with abuse potential of tramadol.
2002 Feb
Stereoselectivity in renal clearance of trans-tramadol and its active metabolite, trans-O-demethyltramadol.
2002 Jan
Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation.
2002 Jan
Use of nonopioid analgesics and adjunctive agents in the management of pain in rheumatic diseases.
2002 Jan
A systematic review of adjuncts for intravenous regional anesthesia for surgical procedures.
2002 Jan
Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care.
2002 Jan
Meeting the therapeutic challenge of the patient with osteoarthritis.
2002 Jan-Feb
Patient reporting of potential adverse drug reactions: a methodological study.
2002 Mar
Tramadol infusion for postthoracotomy pain relief: a placebo-controlled comparison with epidural morphine.
2002 Mar
Patents

Sample Use Guides

Chronic: 25 mg PO every morning initially; increased by 25-50 mg/day every 3 days up to 50-100 mg PO q4-6hr PRN; not to exceed 400 mg/day
Route of Administration: Oral
A malignancy of A549 and PC-9 cells was detected after treatment of 2 μM tramadol for different time (0, 7, 14, or 28 d).
Substance Class Chemical
Created
by admin
on Sat Jun 26 02:49:28 UTC 2021
Edited
by admin
on Sat Jun 26 02:49:28 UTC 2021
Record UNII
39J1LGJ30J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRAMADOL
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
E-265
Code English
ETS6103
Code English
(+/-)-TRAMADOL
Common Name English
(+/-)-CIS-2-((DIMETHYLAMINO)METHYL)-1-(M-METHOXYPHENYL)CYCLOHEXANOL
Common Name English
TRAMADOL [MI]
Common Name English
TRAMADOL [WHO-DD]
Common Name English
CG-315E
Code English
AMANDA
Brand Name English
E265
Code English
ETS-6103
Code English
U-26255A
Code English
TRAMADOL [INN]
Common Name English
TRAMADOL [VANDF]
Common Name English
Classification Tree Code System Code
WHO-VATC QN02AX02
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
WHO-ATC N02AX02
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
WHO-ATC N02AJ13
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
DEA NO. 9278
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
NDF-RT N0000175684
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
WHO-ATC N02AJ14
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
WHO-ATC N02AX52
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
NDF-RT N0000175690
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
WHO-ATC N02AJ15
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
NCI_THESAURUS C241
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
LIVERTOX 986
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
WHO-VATC QN02AX52
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL1237044
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY
WIKIPEDIA
TRAMADOL
Created by admin on Sat Jun 26 02:49:29 UTC 2021 , Edited by admin on Sat Jun 26 02:49:29 UTC 2021
PRIMARY
ECHA (EC/EINECS)
248-319-6
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY
NCI_THESAURUS
C29507
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY
DRUG BANK
DB00193
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY
HSDB
7047
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY
CAS
2914-77-4
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
NON-SPECIFIC STEREOCHEMISTRY
LACTMED
Tramadol
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY
IUPHAR
8286
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY
INN
2722
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY
MESH
D014147
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY
EVMPD
SUB11210MIG
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY
DRUG CENTRAL
2711
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY
RXCUI
10689
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M10996
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
220-831-4
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
ALTERNATIVE
FDA UNII
39J1LGJ30J
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY
CAS
27203-92-5
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY
EPA CompTox
27203-92-5
Created by admin on Sat Jun 26 02:49:28 UTC 2021 , Edited by admin on Sat Jun 26 02:49:28 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
(?)-tramadol inhibits norepinephrine reuptake
ENANTIOMER -> RACEMATE
METABOLIC ENZYME -> SUBSTRATE
MINOR
METABOLIC ENZYME -> INHIBITOR
POTENT
TARGET -> AGONIST
(+)-isomer
COMPETITIVE INHIBITOR
Ki
METABOLIC ENZYME -> SUBSTRATE
MAJOR
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
(+)-Tramadol inhibits serotonin reuptake
METABOLIC ENZYME -> SUBSTRATE
MINOR
METABOLIC ENZYME -> SUBSTRATE
MAJOR
ENANTIOMER -> RACEMATE
Agonist of the ?. opioid receptor and inhibits serotonin reuptake.
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
MAJOR
METABOLITE ACTIVE -> PRODRUG
METABOLITE ACTIVE -> PRODRUG
MAJOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Route of Elimination PHARMACOKINETIC EXCRETED UNCHANGED, RENAL
PHARMACOKINETIC
ORAL BIOAVAILABILITY PHARMACOKINETIC EXTENDED-RELEASE TABLET
PHARMACOKINETIC
MAXIMUM TOLERATED DOSE TOXICITY IMMEDIATE-RELEASE TABLET

Route of Elimination PHARMACOKINETIC PERCENT EXCRETED UNCHANGED
PHARMACOKINETIC
Tmax PHARMACOKINETIC EFFECT OF FOOD
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC MALE
PHARMACOKINETIC
PROTEIN BINDING PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL, IMMEDIATE-RELEASE TABLET (GERIATRICS)
PHARMACOKINETIC
ORAL, IMMEDIATE-RELEASE TABLET (HEPATIC IMPAIRMENT)
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC IMMEDIATE-RELEASE (GERIATRIC 75 YEARS AND OLDER)
PHARMACOKINETIC
O-DESMETHYL-TRAMADOL (M1), IMMEDIATE-RELEASE
PHARMACOKINETIC
IMMEDIATE-RELEASE (HEPATIC IMPAIRMENT)
PHARMACOKINETIC
IV, RENAL IMPAIRMENT (CrCL LESS THAN 30 mL/min)
PHARMACOKINETIC
O-DESMETHYL-TRAMADOL (M1), EXTENDED-RELEASE
PHARMACOKINETIC
EXTENDED-RELEASE
PHARMACOKINETIC
O-DESMETHYL-TRAMADOL (M1), IMMEDIATE-RELEASE (HEPATIC IMPAIRMENT)
PHARMACOKINETIC
O-DESMETHYL-TRAMADOL (M1), IV, RENAL IMPAIRMENT (CrCL LESS THAN 30 mL/min)
PHARMACOKINETIC